Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

NCT00722072 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Sponsor pulled funding and low accrual

Conditions

Breast Cancer

Interventions

DRUG: fulvestrant
DRUG: sorafenib tosylate

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]